ArticleFrontiers in immunology2012
Cross-reactive broadly neutralizing antibodies: timing is everything.
Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection.Journal of acquired immune deficiency syndromes (1999) · 2013Trial
- Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.The Journal of clinical investigation · 2025Article
- Extracellular vesicle isolation methods identify distinct HIV-1 particles released from chronically infected T-cells.Journal of extracellular vesicles · 2024Article
- Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody.iScience · 2023Article
- An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1.ACS omega · 2023Review
- Recent advances on smart glycoconjugate vaccines in infections and cancer.The FEBS journal · 2022Review
- Design of human immunodeficiency virus-1 neutralizing peptides targeting CD4-binding site: An integrative computational biologics approach.Frontiers in medicine · 2022Article
- Microglia in Alzheimer's Disease: A Favorable Cellular Target to Ameliorate Alzheimer's Pathogenesis.Mediators of inflammation · 2022Review
- Therapeutic vaccination of koalas harbouring endogenous koala retrovirus (KoRV) improves antibody responses and reduces circulating viral load.NPJ vaccines · 2020Article
- Follicular T-cell subsets in HIV infection: recent advances in pathogenesis research.Current opinion in HIV and AIDS · 2019Review
- An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.Journal of virology · 2019Article
- Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.Frontiers in neuroscience · 2017Review
- CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children.Frontiers in immunology · 2017Article
- Alterations in B Cell Compartment Correlate with Poor Neutralization Response and Disease Progression in HIV-1 Infected Children.Frontiers in immunology · 2017Article
- An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.Nature microbiology · 2016Article
- An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus.The Journal of general virology · 2015Article
- HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.The Journal of biological chemistry · 2014Article
- Article
- HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Retrovirology · 2013Article
- Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Virologica Sinica · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent surge of research into new broadly neutralizing antibodies in HIV-1 infection has recharged the field of HIV-1 vaccinology. In this review we discuss the currently known broadly neutralizing antibodies and focus on factors that may shape these antibodies in natural infection. We further discuss the role of these antibodies in the clinical course of the infection and consider immunological obstacles in inducing broadly neutralizing antibodies with a vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.